Clinical TopicsGlobal BulletinAll NewsApproval Alert
2 Minute DrillAround the PracticeBetween the LinesBreaking BarriersFace OffFrom All AnglesMeeting of the MindsMorning RoundsOncViewPodcastsReadout 360Sponsored MediaTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Contemporary ConceptsAwareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsored
Career CenterSubscribe
Adverse Effects
Biomarkers
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Hormone-related Cancers
Immunotherapy
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
LymphomaLymphoma
Melanoma
Mesothelioma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Around the Practice
  • Between the Lines
  • Contemporary Concepts
  • Journal
  • OncView
  • Podcasts
  • Readout 360
  • Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
  • Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Adverse Effects
Biomarkers
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Hormone-related Cancers
Immunotherapy
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
LymphomaLymphoma
Melanoma
Mesothelioma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

No Strong Link Between Breast Cancer Risk and Pollutants

September 1, 2002
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 9
Volume 11
Issue 9

BETHESDA, Maryland-Results from the largest epidemiologic investigation of possible links between two major types of environmental pollutants and breast cancer indicate a 50% increase in risk of the disease for women exposed to polycyclic aromatic hydrocarbons (PAHs) at the highest level. However, researchers failed to find an association between organochlorine compounds, which include DDT, and an increased risk of breast cancer.

BETHESDA, Maryland—Results from the largest epidemiologic investigation of possible links between two major types of environmental pollutants and breast cancer indicate a 50% increase in risk of the disease for women exposed to polycyclic aromatic hydrocarbons (PAHs) at the highest level. However, researchers failed to find an association between organochlorine compounds, which include DDT, and an increased risk of breast cancer.

The new findings emerged from two studies conducted as part of the Long Island Breast Cancer Study Project, which Congress mandated in 1993. The two studies involved a total of 1,058 women living in Nassau and Suffolk counties on Long Island, which have disproportionately high breast cancer rates, compared with other counties in New York State.

The goal of the two population-based, case-control studies "was to determine whether breast cancer incidence in these two counties was associated with exposures to environmental contaminants," said Marilie D. Gammon, PhD, who served as principal investigator for both studies. "What we observed did not support that possibility strongly." Dr. Gammon is associate professor of epidemiology, University of North Carolina School of Public Health, Chapel Hill.

PAHs result from incomplete combustion. They are inhaled with such things as cigarette smoke and from the smoke and vehicle exhaust that result from burning fossil fuels, and are ingested by eating grilled and smoked foods.

The compounds are potent mammary carcinogens in rodents, and the federal government has designated several of them as probable or possible human carcinogens. However, researchers have not clearly demonstrated carcinogenic effects in the breasts of women.

Organochlorines include several pesticides (such as DDT); the family of industrial compounds known as PCBs; and the termiticide chlordane. DDT was used widely on Long Island to control mosquitoes and gypsy moths before it was banned in 1972. Several previous epidemiologic studies have indicated a link between organochlorine exposure and breast cancer. However, most such studies have not supported an association of DDT and PCBs with the disease.

In the PAH study, Dr. Gammon and her colleagues focused on PAH-DNA adducts—places where the hydrocarbon attaches to the DNA in cells. Adducts serve as markers for exposure to a chemical and are widely believed to indicate tissue damage. The researchers looked for adducts in cells from blood samples donated by 576 women newly diagnosed with breast cancer and 427 women without breast cancer who served as controls.

"The age-adjusted odds ratio for breast cancer in relation to the highest quintile of adduct levels compared to the lowest was 1.51, with little or no evidence of confounding," the researchers reported. However, they found no consistent evidence of an increased risk of breast cancer with increased adduct levels, and no consistent association of adduct levels and two major causes of PAHs—active smoking and inhaling second-hand cigarette smoke, and eating grilled and smoked foods. "The data indicate that PAH-DNA adduct formation may influence breast cancer development, although the association does not appear to be dose dependent and may have a threshold effect," the team concluded.

Said Dr. Gammon, "Our findings suggest that women’s individual responses to similar PAH exposures might be more relevant to breast cancer development than the absolute amount of PAH," and the team is investigating this issue.

Organochlorines Study

For the study of organochlorines, the researchers analyzed blood from 646 women with newly diagnosed breast cancer and from 429 controls for exposure levels to the target chemicals. No substantial elevation in breast cancer risk was found for the lipid-adjusted serum levels between the highest and lowest quintiles for DDT, DDE, chlordane, and dieldrin and other PCBs. No dose-response relations were identified.

A woman’s risk was not increased in relation to organochlorines among those who had not breast-fed, or were overweight, postmenopausal, or long-time Long Island residents. Whether a woman’s breast cancer was diagnosed as invasive or in situ, or whether the tumor was hormone-receptor positive or negative failed to show an association with organochlorine exposure.

The researchers concluded that the results did not support the notion that exposure to organochlorines increases a woman’s risk of breast cancer. However, the study did not exclude the possibility that organochlorines play an early, subtle role in tumor development.

Dr. Gammon noted that some research suggests that the compounds may be related to breast cancers with clinical characteristics associated with poor survival. "We are continuing to investigate this issue among the women in our study," she said. The two reports appeared in the August issue of Cancer Epidemiology, Biomarkers & Prevention.

Articles in this issue

Tumor-Specific Idiotype Vaccines Promising in B-Cell Lymphomas
Childhood Survivors May Not Know Their Past Rx
Pemetrexed/Gemcitabine Promising in Advanced Pancreatic Cancer
Physician Experience Predicts HIV-Related Mortality
Preliminary Phase III Results for Provenge Vaccine in Prostate Cancer
Eloxatin With 5-FU/LV Approved for Recurrent Colon Cancer
Comprehensive Geriatric Evaluations Improve Care
Nordion’s Monte Carlo Dose Calculation Software Approved
No Strong Link Between Breast Cancer Risk and Pollutants
Imatinib Inactive in Sarcomas That Lack C-KIT/PDGF
Task Force Recommends Screening for All Age 50 and Over
No Link Between Breast Cancer Risk and Pollutants
NIH, Drug Industry Target Barriers to Patient Accrual in Clinical Trials
Medicare Puts PET for Thyroid Cancer, Soft Tissue Sarcoma on Hold
Cranial Radiotherapy for Childhood ALL Linked to Adult Obesity
Recent Videos
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
Related Content
Advertisement

96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States

96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States

Elyse Swallow;Jessica Maitland;Kirthana Sarathy;Ellen Sears;Yasir Nagarwala;Janelle DePalantino;Eric Kruep;Corey Pelletier;Sebastian Kloss;Tomer Wasserman
April 18th 2025
Article

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.

Bria-IMT Enhances Survival vs Sacituzumab Govitecan in HR+ Breast Cancer

Roman Fabbricatore
April 17th 2025
Article

No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.


A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Reducing Post-Mastectomy Disparities in Breast Cancer Minority Populations

Rachel A. Greenup, MD, MPH
December 23rd 2024
Podcast

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.


100 Non-Pharmacological Interventions for Managing Abemaciclib-Associated Adverse Events in Patients With Early/Advanced HR+/HER2– Breast Cancer: A US-Based Health Care Provider Survey

100 Non-Pharmacological Interventions for Managing Abemaciclib-Associated Adverse Events in Patients With Early/Advanced HR+/HER2– Breast Cancer: A US-Based Health Care Provider Survey

Alexandra Vitko;Pamela K Ginex;Kelli Thoele;Qinli Lily Ma;Astra Liepa;Wambui Gathirua-Mwangi;Elyse Hall Panjic, PharmD, BCOP;Engels Chou;Jodi L Taraba;Hilary Ellis;Charlotte Clewes;Joanna de Courcy;Hope S. Rugo, MD
April 15th 2025
Article

102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer

102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer

Charlotta Wadsten;Karuna Mittal;Pat W. Whitworth;Chirag Shah, MD;Frank Vicini, MD;Naamit Gerber;Melissa Krystel-Whittemore;Clayton C. Yates;Balasubramanyam Karanam;Walter Bell;Charles E. Cox, MS, FACS;Abigail Beard;Geza Acs;Steven C. Shivers;David J. Dabbs;Jess Savala;Mark Mentrikoski;Troy Bremer
April 14th 2025
Article
Related Content
Advertisement

96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States

96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States

Elyse Swallow;Jessica Maitland;Kirthana Sarathy;Ellen Sears;Yasir Nagarwala;Janelle DePalantino;Eric Kruep;Corey Pelletier;Sebastian Kloss;Tomer Wasserman
April 18th 2025
Article

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.

Bria-IMT Enhances Survival vs Sacituzumab Govitecan in HR+ Breast Cancer

Roman Fabbricatore
April 17th 2025
Article

No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.


A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Reducing Post-Mastectomy Disparities in Breast Cancer Minority Populations

Rachel A. Greenup, MD, MPH
December 23rd 2024
Podcast

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.


100 Non-Pharmacological Interventions for Managing Abemaciclib-Associated Adverse Events in Patients With Early/Advanced HR+/HER2– Breast Cancer: A US-Based Health Care Provider Survey

100 Non-Pharmacological Interventions for Managing Abemaciclib-Associated Adverse Events in Patients With Early/Advanced HR+/HER2– Breast Cancer: A US-Based Health Care Provider Survey

Alexandra Vitko;Pamela K Ginex;Kelli Thoele;Qinli Lily Ma;Astra Liepa;Wambui Gathirua-Mwangi;Elyse Hall Panjic, PharmD, BCOP;Engels Chou;Jodi L Taraba;Hilary Ellis;Charlotte Clewes;Joanna de Courcy;Hope S. Rugo, MD
April 15th 2025
Article

102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer

102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer

Charlotta Wadsten;Karuna Mittal;Pat W. Whitworth;Chirag Shah, MD;Frank Vicini, MD;Naamit Gerber;Melissa Krystel-Whittemore;Clayton C. Yates;Balasubramanyam Karanam;Walter Bell;Charles E. Cox, MS, FACS;Abigail Beard;Geza Acs;Steven C. Shivers;David J. Dabbs;Jess Savala;Mark Mentrikoski;Troy Bremer
April 14th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.